User menu

CB1 cannabinoid receptor antagonism for treating inflammation and arthritis

Bibliographic reference Lambert, Didier. CB1 cannabinoid receptor antagonism for treating inflammation and arthritis. In: Expert Opinion on Therapeutic Patents, Vol. 17, no. 8, p. 1027-1031 (2007)
Permanent URL
  1. Howlett Allyn C., Breivogel Christopher S., Childers Steven R., Deadwyler Samuel A., Hampson Robert E., Porrino Linda J., Cannabinoid physiology and pharmacology: 30 years of progress, 10.1016/j.neuropharm.2004.07.030
  2. Lambert Didier M., Fowler Christopher J., The Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications, 10.1021/jm058183t
  3. Lange Jos H.M., Kruse Chris G., Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists, 10.1016/s1359-6446(05)03427-6
  4. Muccioli G., Lambert D., Current Knowledge on the Antagonists and Inverse Agonists of Cannabinoid Receptors, 10.2174/0929867054020891
  5. Muccioli Giulio G, Lambert Didier M, Latest advances in cannabinoid receptor antagonists and inverse agonists, 10.1517/13543776.16.10.1405
  6. Mackie K., Distribution of Cannabinoid Receptors in the Central and Peripheral Nervous System, Handbook of Experimental Pharmacology ISBN:354022565X p.299-325, 10.1007/3-540-26573-2_10
  7. Mackie Ken, CANNABINOID RECEPTORS AS THERAPEUTIC TARGETS, 10.1146/annurev.pharmtox.46.120604.141254
  8. Howlett A. C., International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors, 10.1124/pr.54.2.161
  9. Wilson Rachel I., Nicoll Roger A., 10.1038/35069076
  10. Wilson R. I., Endocannabinoid Signaling in the Brain, 10.1126/science.1063545
  11. Henness Sheridan, Robinson Dean M, Lyseng-Williamson Katherine A, Rimonabant : , 10.2165/00003495-200666160-00006
  12. Bifulco M., Grimaldi C., Gazzerro P., Pisanti S., Santoro A., Rimonabant: Just an Antiobesity Drug? Current Evidence on Its Pleiotropic Effects, 10.1124/mol.106.033118
  13. Patel P. N., Pathak R., Rimonabant: A novel selective cannabinoid-1 receptor antagonist for treatment of obesity, 10.2146/060258
  14. Lafontan M., Piazza P.V., Girard J., Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients, 10.1016/j.diabet.2007.02.001
  15. LE, J. Pharmacol. Exp. Ther., 312, 875 (2005)
  16. Van Gaal Luc F, Rissanen Aila M, Scheen André J, Ziegler Olivier, Rössner Stephan, Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study, 10.1016/s0140-6736(05)66374-x
  17. Scheen André J, Finer Nick, Hollander Priscilla, Jensen Michael D, Van Gaal Luc F, Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study, 10.1016/s0140-6736(06)69571-8
  18. Teixeira-Clerc Fatima, Julien Boris, Grenard Pascale, Van Nhieu Jeanne Tran, Deveaux Vanessa, Li Liying, Serriere-Lanneau Valérie, Ledent Catherine, Mallat Ariane, Lotersztajn Sophie, CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis, 10.1038/nm1421
  19. RACHELEFSKY G, OPELZ G, MICKEY M, LESSIN P, KIUCHI M, SILVERSTEIN M, STIEHM E, Intact humoral and cell-mediated immunity in chronic marijuana smoking, 10.1016/0091-6749(76)90192-5
  20. Croxford J. Ludovic, Yamamura Takashi, Cannabinoids and the immune system: Potential for the treatment of inflammatory diseases?, 10.1016/j.jneuroim.2005.04.023
  21. Valenzano Kenneth J., Tafesse Laykea, Lee Gary, Harrison James E., Boulet Jamie M., Gottshall Susan L., Mark Lilly, Pearson Michelle S., Miller Wendy, Shan Shen, Rabadi Leyana, Rotshteyn Yakov, Chaffer Suzanne M., Turchin Paul I., Elsemore David A., Toth Mathew, Koetzner Lee, Whiteside Garth T., Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy, 10.1016/j.neuropharm.2004.12.008
  22. Gutierrez T, Farthing J N, Zvonok A M, Makriyannis A, Hohmann A G, Activation of peripheral cannabinoid CB1and CB2receptors suppresses the maintenance of inflammatory nociception: a comparative analysis, 10.1038/sj.bjp.0706984
  23. Guindon J, Desroches J, Beaulieu P, The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2receptors, 10.1038/sj.bjp.0706990
  24. Romero-Sandoval Alfonso, Eisenach James C., Spinal Cannabinoid Receptor Type 2 Activation Reduces Hypersensitivity and Spinal Cord Glial Activation after Paw Incision : , 10.1097/01.anes.0000264765.33673.6c
  25. Whiteside G, Lee G., Valenzano K, The Role of the Cannabinoid CB2 Receptor in Pain Transmission and Therapeutic Potential of Small Molecule CB2 Receptor Agonists, 10.2174/092986707780363023
  26. Giblin Gerard M. P., O'Shaughnessy Celestine T., Naylor Alan, Mitchell William L., Eatherton Andrew J., Slingsby Brian P., Rawlings D. Anthony, Goldsmith Paul, Brown Andrew J., Haslam Carl P., Clayton Nick M., Wilson Alex W., Chessell Iain P., Wittington Andrew R., Green Richard, Discovery of 2-[(2,4-Dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a Selective CB2 Receptor Agonist for the Treatment of Inflammatory Pain, 10.1021/jm061195+
  27. Croci T, Zarini E, Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats : Rimonabant and arthritis in obese rats, 10.1038/sj.bjp.0707138
  28. Costa B, Rimonabant: more than an anti-obesity drug? : Commentary, 10.1038/sj.bjp.0707139
  29. Petrosino Stefania, Palazzo Enza, de Novellis Vito, Bisogno Tiziana, Rossi Francesco, Maione Sabatino, Di Marzo Vincenzo, Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats, 10.1016/j.neuropharm.2006.08.011